In the treatment of breakpoint cluster region-Abelson (BCR-ABL)-positive chronic myeloid leukemia (CML) using BCR-ABL inhibitors, the appearance of a gatekeeper mutation (T315I) in BCR-ABL is a serious issue. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.